High Growth Tech Stocks in Europe for July 2025

As European markets experience tentative optimism fueled by potential EU-U.S. trade agreements, the pan-European STOXX Europe 600 Index has seen a modest rise of 0.54%, reflecting a cautious yet hopeful sentiment amid ongoing global economic uncertainties. In this environment, identifying high growth tech stocks in Europe involves looking for companies that demonstrate resilience and adaptability to shifting trade dynamics and economic conditions while maintaining robust innovation capabilities.

Top 10 High Growth Tech Companies In Europe

Click here to see the full list of 232 stocks from our European High Growth Tech and AI Stocks screener.

Let's review some notable picks from our screened stocks.

Lectra (ENXTPA:LSS)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Lectra SA offers industrial intelligence solutions to the fashion, automotive, and furniture industries across Europe, the Americas, the Asia Pacific, and globally with a market capitalization of €986.24 million.

Operations: The company generates revenue from its industrial intelligence solutions, with the EMEA region contributing €220.46 million, followed by the Americas at €176.26 million and Asia-Pacific at €134.84 million.

Lectra, a trailblazer in integrating digital solutions like Valia Furniture and Valia Fashion into traditional industries, is reshaping how businesses approach production efficiency and scalability. With recent expansions into key markets such as Mexico and Brazil, Lectra's platforms offer real-time data integration that significantly cuts down material waste and enhances operational flexibility. This strategic move not only broadens their global footprint but also aligns with the industry's shift towards more sustainable manufacturing practices. The adoption of these advanced systems by companies like Edgecombe Furniture and Chicago Protective Apparel underscores Lectra's pivotal role in driving the next generation of industry 4.0-ready enterprises, evidenced by a notable 10% potential reduction in material consumption for Edgecombe, translating to substantial cost savings ($14,000 in one instance). These developments highlight Lectra’s commitment to innovation—bolstering its reputation as a key player in high-growth tech sectors while promising robust future prospects through smart technology integrations.

• Click to explore a detailed breakdown of our findings in Lectra's health report.

• Review our historical performance report to gain insights into Lectra's's past performance.

Ubisoft Entertainment (ENXTPA:UBI)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Ubisoft Entertainment SA is a global company that creates and manages video games across various platforms, including consoles, PCs, smartphones, and tablets, with a market capitalization of approximately €1.27 billion.

Operations: Ubisoft Entertainment SA generates revenue primarily through publishing and cloud gaming production, with the latter contributing €1.51 billion. The company's operations span both physical and digital formats across Europe, North America, and international markets.

Ubisoft Entertainment, navigating through a challenging landscape, showcases resilience with its strategic pivot towards high-growth sectors like digital and interactive media. Despite a recent financial setback, reporting a net loss of €159 million from sales of €1.9 billion—a stark contrast to the previous year's profit—the company is poised for recovery. Forecasted to turn profitable within three years, Ubisoft's anticipated annual earnings growth rate stands at an impressive 64.13%. This potential turnaround is underpinned by consistent R&D investments aimed at innovating gaming experiences and expanding digital offerings. With revenue growth expected to outpace the French market at 6% annually compared to 5.1%, Ubisoft’s focus on enhancing user engagement through advanced gaming technologies could redefine its market standing amidst volatile share prices.

• Click here to discover the nuances of Ubisoft Entertainment with our detailed analytical health report.

• Examine Ubisoft Entertainment's past performance report to understand how it has performed in the past.

Formycon (XTRA:FYB)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Formycon AG is a biotechnology company focused on developing biosimilar drugs in Germany and Switzerland, with a market capitalization of €535.00 million.

Operations: The biotechnology firm generates revenue primarily from its drug delivery systems, amounting to €69.67 million.

Formycon, a trailblazer in biosimilars, is demonstrating significant strides in the high-growth tech sector of biopharmaceuticals. With an 18.8% annual revenue growth surpassing Germany's 6%, and an expected earnings surge of 78.91%, the company is strategically positioning itself for profitability within three years. Recent developments include successful patient enrollment in the Dahlia PK study and strategic partnerships for commercializing its biosimilar products across Europe, enhancing its competitive edge in the industry. These efforts are supported by robust R&D investments that underscore Formycon's commitment to innovation and market leadership in biosimilars.

• Delve into the full analysis health report here for a deeper understanding of Formycon.

• Learn about Formycon's historical performance.

Taking Advantage

• Discover the full array of 232 European High Growth Tech and AI Stocks right here.
• Have a stake in these businesses? Integrate your holdings into Simply Wall St's portfolio for notifications and detailed stock reports.
• Take control of your financial future using Simply Wall St, offering free, in-depth knowledge of international markets to every investor.

Interested In Other Possibilities?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com